Ceftazidime

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

1985

www.ebi.ac.uk

First approval year: 1985
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Ceftazidime
www.ebi.ac.uk

Molecular weight: 546.59
www.ebi.ac.uk

Structure (SMILES): CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)O
www.ebi.ac.uk

ceftazidime
Ceftazidime
ceftazidime component of avycaz
Ceftazidime component of avycaz
ceftazidime component of zavicefta
Ceftazidime component of zavicefta
ceptaz
Ceptaz
fortam
Fortam
fortaz
Fortaz
fortum
Fortum
kefazim
Kefazim
pentacef
Pentacef
tazicef
Tazicef
tazidime
Tazidime

ceftazidima
Ceftazidima
ceftazidime
Ceftazidime
Ceftazidime (arginine formulation)
ceftazidime [INN]
CEFTAZIDIME [MI]
Ceftazidime [WHO-DD]
ceftazidime anhydrous
Ceftazidime anhydrous
ceftazidime arginine formulation
ceftazidime hydrate
Ceftazidime hydrate
ceftazidime inn
ceftazidime mi
ceftazidime pentahydrate
Ceftazidime pentahydrate
ceftazidime who dd
gr 20263
GR 20263
GR-20263
j01dd07
J01DD07
ly 139381
LY 139381

And 3 more, listed on the interactive page.

ATC classification codes

J01DD02

Sources for recorded values

www.ebi.ac.uk

CAS registry numbers

72558-82-8

ChEMBL ID: CHEMBL44354
www.ebi.ac.uk

InChIKey: ORFOPKXBNMVMKC-DWVKKRMSSA-N
www.ebi.ac.uk

FDA ingredient codes (UNII)

DZR1ENT301

5481173
57514439
73415817

2191
1545984

Applicant: PAI HOLDINGS PHARM
Approval date: 19 Jul 1985
Application number: NDA050578

Patents: 0
Designations: 1
First in class: No
Fast track: No
Breakthrough designation: No
Orphan designation: No
Priority review: Yes
Orphan exclusivity: No
Accelerated approval: No
Availability: Prescription only
Boxed warning: Yes

United States (FDA): Approved

Pharmacology name: ceftazidime
Type: Synthetic organic
Drug name stem: cef-
Approval recorded by Guide to Pharmacology: Yes

Administration routes

Parenteral

Mechanism
Bacterial penicillin-binding protein inhibitor
Action type
Inhibitor
Target
Bacterial penicillin-binding protein
Protein identifier
P02918
Mechanism
Bacterial penicillin-binding protein inhibitor
Action type
Inhibitor
Target
Bacterial penicillin-binding protein
Protein identifier
P02919
Mechanism
Bacterial penicillin-binding protein inhibitor
Action type
Inhibitor
Target
Bacterial penicillin-binding protein
Protein identifier
P08506
Mechanism
Bacterial penicillin-binding protein inhibitor
Action type
Inhibitor
Target
Bacterial penicillin-binding protein
Protein identifier
P0AD65
Mechanism
Bacterial penicillin-binding protein inhibitor
Action type
Inhibitor
Target
Bacterial penicillin-binding protein
Protein identifier
P0AD68
Mechanism
Bacterial penicillin-binding protein inhibitor
Action type
Inhibitor
Target
Bacterial penicillin-binding protein
Protein identifier
P0AEB2
Mechanism
Bacterial penicillin-binding protein inhibitor
Action type
Inhibitor
Target
Bacterial penicillin-binding protein
Protein identifier
P24228

Open Targets mechanisms

Mechanism
Bacterial penicillin-binding protein inhibitor
Action type
Inhibitor
Target
Bacterial penicillin-binding protein

Action type
Inhibitor
Gene symbol
mrcA
Protein identifier
P02918
Organism
Escherichia coli (strain K12)
Action type
Inhibitor
Gene symbol
mrcB
Protein identifier
P02919
Organism
Escherichia coli (strain K12)
Action type
Inhibitor
Gene symbol
ftsI
Protein identifier
P0AD68
Organism
Escherichia coli (strain K12)

Condition
Infections
Highest recorded phase
4
Condition identifier
EFO:0000544
Subject identifier
D007239
Condition
Intraabdominal Infections
Highest recorded phase
4
Condition identifier
EFO:0000544
Subject identifier
D059413
Condition
Skin Diseases
Highest recorded phase
3
Condition identifier
EFO:0000701
Subject identifier
D012871
Condition
Bacterial Infections
Highest recorded phase
4
Condition identifier
EFO:0000771
Subject identifier
D001424
Condition
Osteomyelitis
Highest recorded phase
0.5
Condition identifier
EFO:0003102
Subject identifier
D010019
Condition
Urinary Tract Infections
Highest recorded phase
4
Condition identifier
EFO:0003103
Subject identifier
D014552
Condition
Pneumonia
Highest recorded phase
4
Condition identifier
EFO:0003106
Subject identifier
D011014
Condition
Peritonitis
Highest recorded phase
4
Condition identifier
EFO:0008588
Subject identifier
D010538
Condition
Meningitis, Bacterial
Highest recorded phase
2
Condition identifier
EFO:1000831
Subject identifier
D016920
Condition
Parametritis
Highest recorded phase
4
Condition identifier
EFO:1001084
Subject identifier
D010249
Condition
Pyelonephritis
Highest recorded phase
4
Condition identifier
EFO:1001141
Subject identifier
D011704
Condition
Enterobacteriaceae Infections
Highest recorded phase
3
Condition identifier
EFO:1001313
Subject identifier
D004756
Condition
Staphylococcal Skin Infections
Highest recorded phase
3
Condition identifier
EFO:1001849
Subject identifier
D013207
Condition
Esophageal Achalasia
Highest recorded phase
2
Condition identifier
HP:0002571
Subject identifier
D004931
Condition
Cystic Fibrosis
Highest recorded phase
1
Condition identifier
MONDO:0009061
Subject identifier
D003550

Condition identifier
EFO_0000544
Condition identifier
EFO_0000544
Highest recorded phase
4
Condition identifier
EFO_0000771
Condition identifier
EFO_0003102
Condition identifier
EFO_0003103
Condition identifier
EFO_0003106
Condition identifier
EFO_0005741
Condition identifier
EFO_0006834
Condition identifier
EFO_0008588
Condition identifier
EFO_1000025
Condition identifier
EFO_1000831
Highest recorded phase
2
Condition identifier
EFO_1001084
Condition identifier
EFO_1001141
Condition identifier
EFO_1001272
Condition identifier
EFO_1001313
Highest recorded phase
3
Condition identifier
EFO_1001865
Highest recorded phase
3
Condition identifier
HP_0000010
Condition identifier
HP_0001082
Condition identifier
HP_0001082
Highest recorded phase
4
Condition identifier
HP_0001945
Highest recorded phase
2
Condition identifier
HP_0002571
Condition identifier
HP_0100523
Condition identifier
HP_0100523
Highest recorded phase
4
Condition identifier
HP_0100806
Condition identifier
HP_0100806
Highest recorded phase
4

And 20 more, listed on the interactive page.

Warnings

Warning
Black Box Warning

Open Targets warnings

Warning
Black Box Warning
Country
United States

Event
acute kidney injury
Reports
93
Reporting signal score
93.0508
Event
agranulocytosis
Reports
21
Reporting signal score
25.385
Event
blood pressure diastolic abnormal
Reports
10
Reporting signal score
31.6515
Event
cholestasis
Reports
25
Reporting signal score
33.2765
Event
choroiditis
Reports
37
Reporting signal score
201.628
Event
clostridium difficile colitis
Reports
24
Reporting signal score
49.5173
Event
coma
Reports
28
Reporting signal score
27.0469
Event
condition aggravated
Reports
83
Reporting signal score
46.5687
Event
congestive hepatopathy
Reports
7
Reporting signal score
34.9917
Event
distal intestinal obstruction syndrome
Reports
6
Reporting signal score
24.9769
Event
drug reaction with eosinophilia and systemic symptoms
Reports
78
Reporting signal score
166.919
Event
drug resistance
Reports
36
Reporting signal score
56.7188
Event
encephalopathy
Reports
22
Reporting signal score
24.836
Event
endometrial disorder
Reports
10
Reporting signal score
43.7162
Event
endophthalmitis
Reports
62
Reporting signal score
213.024
Event
enterococcus test positive
Reports
10
Reporting signal score
39.3812
Event
eosinophilia
Reports
36
Reporting signal score
65.091
Event
eye pain
Reports
47
Reporting signal score
91.2754
Event
fall
Reports
2
Reporting signal score
20.4168
Event
fatigue
Reports
5
Reporting signal score
38.99
Event
fibrosis
Reports
10
Reporting signal score
23.4822
Event
fungaemia
Reports
8
Reporting signal score
24.7778
Event
fungal sepsis
Reports
11
Reporting signal score
50.2068
Event
gamma-glutamyltransferase increased
Reports
20
Reporting signal score
19.475
Event
histiocytosis haematophagic
Reports
10
Reporting signal score
21.933

And 39 more, listed on the interactive page.

NCT00173901
clinicaltrials.gov
NCT00360607
clinicaltrials.gov
NCT00752219
clinicaltrials.gov
NCT01726023
clinicaltrials.gov
NCT02475733
clinicaltrials.gov
NCT04126031
clinicaltrials.gov
NCT05258851
clinicaltrials.gov
NCT00210899
clinicaltrials.gov
NCT00210964
clinicaltrials.gov
NCT00229008
clinicaltrials.gov
NCT00786305
clinicaltrials.gov
NCT02837835
clinicaltrials.gov
NCT04774094
clinicaltrials.gov
NCT00690378
clinicaltrials.gov
NCT00921024
clinicaltrials.gov
NCT02497781
clinicaltrials.gov
NCT00752882
clinicaltrials.gov
NCT00823238
clinicaltrials.gov
NCT01595438
clinicaltrials.gov
NCT01599806
clinicaltrials.gov
NCT02099240
clinicaltrials.gov
NCT02795949
clinicaltrials.gov
NCT02872038
clinicaltrials.gov
NCT03404739
clinicaltrials.gov
NCT03978091
clinicaltrials.gov

Dose: 2.5 grams
Route: Intravenous
How often: Every 8 hours

Hydrogen bond acceptors: 11
Hydrogen bond donors: 3
Polar surface area: 191.22
Calculated partition coefficient (ALogP): -1.3
Calculated partition coefficient (XLogP): 0.4
Prodrug: No
Chirality: Single enantiomer
Inorganic: No
Rule-of-five violations: 2
Rotatable bonds: 9
Heavy atoms: 37
Molecular formula: C22H22N6O7S2
Monoisotopic mass: 546.09913941
Natural product: Yes

Recorded assays: 5,874
Active assays: 86

Confirmatory
Other

Third Generation Cephalosporins
id.nlm.nih.gov

Oral bioavailability

Median: 0
Mean: 0
Minimum: 0
Maximum: 0
Unit: %
Assays: 1
Standard deviation: 0
Summary method: median
Censored results excluded: 0
Other units excluded: 0
Unknown units excluded: 0

Measurement types

Related records

Trials (78)

A Clinical Study of YK-1169 Versus Ceftazidime-Avibactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections
A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections
A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis
A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers
A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia
A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis
A Study of Avycaz (Ceftazidime/Avibactam) Pharmacokinetics/Pharmacodynamics (PK/PD) in Critically Ill Patients
A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately
A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP
A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan
A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam
Adverse Drug Reactions of Different Brands of Ceftazidime Injection
Antibiotic Therapy vs Laparscopic Appendectomy in Pediatric Chronic Appendicitis
Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever
Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients

Approved for (11)

In development for (10)

Achalasia Phase 2
Acute pyelonephritis Phase 3
Bacterial meningitis Phase 2
Chronic obstructive pulmonary disease Phase 2
Cystic fibrosis Phase 1
Meningitis Phase 2
Neutropenia Phase 2
Osteomyelitis Early phase 1
Skin disorder Phase 3
Staphylococcal infection Phase 3

Ceftazidime

Development status

Names and chemistry

Brand names (22)

Other names (28)

Identifiers

PubChem compound IDs (3)

RxNorm IDs (RxCUI) (2)

Regulatory information

United States

Other regulatory facts

Approval status

Pharmacology

Drug classification

Administration routes

Mechanisms of action (7)

Open Targets mechanisms

DrugCentral mechanisms (3)

Investigated indications (15)

Open Targets indications (45)

Warnings

Open Targets warnings

Reported adverse events (64)

Trial references (25)

Dosing

Chemical properties

Evidence counts

Active assay types (2)

Pharmacologic actions

Biological measurements

Observed measurements

Oral bioavailability

Measurement types

Related records

Trials (78)

Approved for (11)

In development for (10)

Other linked conditions (4)